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Abstract
Aims: Patients with bicuspid valves represent a challenging anatomical subgroup for transcath-
eter aortic valve implantation (TAVI). This analysis evaluated the clinical outcomes of the fully
repositionable and retrievable Lotus Valve System in patients with bicuspid aortic valves
enrolled in the RESPOND post-market registry.
Methods and Results: The prospective, open-label RESPOND study enrolled 1,014 patients at
41 centers in Europe, New Zealand, and Latin America, 31 (3.1%) of whom had bicuspid aortic
valves. The mean age in the bicuspid patient cohort was 76.4 years, 64.5% were male, and the
baseline STS score was 6.0 ± 10.2. Procedural success was 100%, with no cases of malposition-
ing, valve migration, embolization, or valve-in-valve. Repositioning was attempted in 10 cases
(32.3%). There was one death (3.2%) and one stroke (3.2%) at 30-day follow-up. Mean AV gradi-
ent was reduced from 48.7 ± 17.0 mmHg at baseline to 11.8 ± 5.1 mmHg at hospital discharge
(P < 0.001); mean effective orifice area (EOA) was increased from 0.6 ± 0.2 cm2 to 1.7 ± 0.4 cm2
(P < 0.001). There were no cases of moderate or severe paravalvular leak (PVL) adjudicated by
the core laboratory; four subjects (13.8%) had mild PVL, 5 (17.2%) had trace PVL. The rate of
pacemaker (PM) implantation for PM-naïve patients was 22.2% (6/27).
Conclusions: Data from the RESPOND registry demonstrate good clinical and echocardio-
graphic outcomes up to 1 year postimplantation in patients with bicuspid aortic valves using the
repositionable Lotus Valve.
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1 | INTRODUCTION
Bicuspid valves are one of the most common congenital aortic valve
anomalies, present in up to 2% of the population.1,2 Compared to tri-
cuspid valves, bicuspid valves have a larger annulus perimeter, an
asymmetrical valve orifice, and more heavily calcified leaflets/raphe.3,4
Patients with a bicuspid aortic valve are at increased risk for aortic
stenosis, aortic dilation, aneurysm, and dissection.3,4 While transcath-
eter aortic valve implantation (TAVI) is an established treatment
option for patients with symptomatic aortic stenosis who are at high
risk for surgical valve replacement,5,6 patients with bicuspid valves
have been excluded from most TAVI clinical trials and bicuspid-TAVI
data are limited. Demonstrating safety and efficacy in bicuspid valves
is essential for TAVI devices, particularly if TAVI is to be extended into
lower risk populations in whom bicuspid anatomy is more prevalent.
Previous data have consistently shown worse outcomes following
TAVI in bicuspid anatomy, including increased paravalvular leak (PVL),
nonuniform/noncircular valve deployment, reduced procedural
success, device migration/embolisation, malfunction, and annular
rupture.7–13 More recent studies have shown that outcomes may be
better with newer generation valves.8 The Boston Scientific Lotus
Valve has several features which may be of benefit in patients with
bicuspid anatomy, including a sealing skirt to reduce PVL, deployment
via gradual mechanical expansion, and full retrievability and reposi-
tionability. The REpostionable Percutaneous Replacement of stenotic
aortic valve through Implantation of Lotus Valve System: Evaluation
of safety and performance (REPRISE II)14 and the REpositionable
Percutaneous Replacement of stenotic aortic valve through Implanta-
tion of Lotus Valve System—Randomized Clinical Evaluation (REPRISE
III)15 trials excluded patients with bicuspid valves.
The RESPOND study evaluated TAVI with the Lotus Valve when
used in routine clinical practice, including in patients with bicuspid aortic
valve anatomy. This subanalysis of RESPOND evaluates 30-day and
1-year outcomes with Lotus in patients with bicuspid aortic valves.
2 | METHODS
2.1 | Study design and device details
The REpositionable Lotus Valve System—Post-market evaluation of
real world clinical outcomes (RESPOND) study is a prospective, open
label, single arm, multi-center, post-market registry from 41 centers in
Europe, New Zealand, and Latin America. The study design has been
previously described.16 Data collection occurred at baseline, index
procedure, discharge and at 30 days and 1 year postprocedure for all
enrolled subjects.
The protocol was approved by the locally appointed institutional
review boards/ethics committees, and the study was conducted in
accordance with the International Conference on Harmonization Guide-
lines for Good Clinical Practice and the ethical principles outlined in the
Declaration of Helsinki. All patients gave written informed consent. The
study was registered with ClinicalTrials.gov (NCT#02031302). The data
and study protocol for this clinical trial may be made available to other
researchers in accordance with Boston Scientific's Data Sharing Policy
(http://www.bostonscientific.com/en-US/data-sharing-requests.html).
The Lotus Valve System consists of a bioprosthetic aortic valve
premounted on a preshaped delivery catheter. Novel features of the
Lotus Valve System include an adaptive seal designed to mitigate PVL,
controlled mechanical expansion, and the ability to fully recapture or
reposition the valve prior to release. Detailed descriptions of the
Lotus Valve System have been previously published.17,18
2.2 | Outcomes measures
Endpoints were assessed according to Valve Academic Research Con-
sortium (VARC)-2 definitions.19 The primary endpoint for RESPOND
was all-cause mortality at 30 days and 1 year in the intent-to-treat pop-
ulation. Secondary endpoints included in-hospital mortality, the compos-
ite of all-cause mortality and disabling stroke at 30 days and 1 year, and
grade of paravalvular aortic valve regurgitation at discharge and 1 year.
Major clinical events (i.e., all-cause mortality and stroke events) were
adjudicated by an Independent Medical Reviewer (IMR). All baseline and
follow-up echocardiography data were evaluated by an independent
core laboratory (Cardialysis Core Laboratory, Rotterdam, Netherlands).
For this subanalysis, the preliminary identification of bicuspid
anatomy was site-reported, and verified on the basis of echocardiog-
raphy and/or computerized tomography (CT) coronary angiography.
Systematic review of CT angiograms was performed by one of the
authors (LVG) using 3Mensio software, and each valve was defined as
type 0, type 1, or type 2 according to Sievers' valve classification
Scheme20 (Figure 1). Four patients in the bicuspid cohort were initially
characterized as having “functional” bicuspid valves; in each of these
cases, CT demonstrated fusion between the right—and noncoronary
cusps. Thus, these four patients were classified as having Sievers type
FIGURE 1 Bicuspid valve types. The Sievers' valve classification
scheme20 was used to define each bicuspid valve as type 0, type 1, or
type 2 [Color figure can be viewed at wileyonlinelibrary.com]
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1 valves. No specific guidance for the selection of valve size in bicus-
pid valves was provided and the final decision was at the discretion of
the operator. This is the first registry to date to employ the use of an
independent clinical event committee as well as to assess both CT and
echo data for bicuspid valve validation and characterization.
3 | RESULTS
3.1 | Study participants and baseline characteristics
The RESPOND post-market registry enrolled 1,014 patients between
May 2014 and February 2016; 31 of the 996 patients implanted with
a Lotus Valve were identified as having bicuspid anatomy. Most base-
line characteristics for bicuspid and tricuspid patients from RESPOND
were similar. Significant baseline differences existed for average age
(76.4 ± 7.9 years bicuspid vs. 80.9 ± 6.4 years tricuspid; P < 0.001),
history of coronary artery disease (CAD) (25.8% bicuspid vs. 57.1% tri-
cuspid; P = 0.001), and percutaneous coronary intervention (PCI)
(12.9% bicuspid vs. 30.4% tricuspid; P < 0.05) (Table 1).
The majority of the bicuspid patients (74.2% [23/31]) had Sievers
type 1 valve anatomy (21 L-R, 2 R-N); 16.1% (5/31) had type 0 valves,
3.2% (1/31; 1 R-N) had type 2 valves, and 6.5% (2/31) were unable to
be classified due to scan quality.
Core laboratory-adjudicated baseline echocardiography was sig-
nificantly different between the two groups. The mean effective aortic
orifice area (EOA) was 0.6 ± 0.2 cm2 for bicuspid and 0.7 ± 0.2 cm2
for tricuspid (P = 0.008) and the mean aortic valve gradient was
48.7 ± 17.0 mmHg for bicuspid and 37.6 ± 15.3 mmHg for tricuspid
(P < 0.001). There were no significant differences in aortic regurgita-
tion (AR) at baseline (Severe AR: 3.7% for bicuspid, 2.2% for tricuspid;
Moderate AR: 18.5% for bicuspid, 14.2% for tricuspid; None-Mild AR:
77.8% for bicuspid, 83.6% for tricuspid; P=NS for all). Site-reported
aortic valve calcification was not significantly different in patients with
bicuspid valves versus patients with tricuspid aortic valves (Table 1),
nor was site-reported aortic annulus diameter (25.1 mm for bicuspid,
24.4 mm for tricuspid; P = 0.085). Based on preprocedural echocardi-
ography, left ventricular ejection fraction was similar in both groups
(50.9 ± 15.3% for bicuspid, 54.8 ± 13.0% for tricuspid; P = 0.112).
There were 11 (35.4%) aortic root aneurysms (defined as maximum
diameter of ascending aorta >40 mm) reported in the bicuspid cohort
of the RESPOND registry.
3.2 | Procedural success and details
Both the bicuspid and tricuspid cohorts demonstrated high rates of pro-
cedural success. Pre-dilatation was performed significantly more often in
the bicuspid cases than in the tricuspid cases (80.0% [24/30] for bicus-
pid, 53.0% [500/943] for tricuspid; P = 0.004). Correct positioning of a
single prosthetic valve in the proper anatomical location occurred in
100% of the bicuspid cases—there were no cases of migration, emboliza-
tion, or deployment of a second valve. Repositioning was attempted in
10 bicuspid patients (32%) and 299 tricuspid patients (31%). If
attempted, repositioning was successful in 9 of 10 attempts (90%) for
bicuspid patients and in 287 of 299 attempts (96.0%) for tricuspid
patients. In the one bicuspid patient in whom repositioning was deemed
unsuccessful, the site had reported “moderate aortic regurgitation
TABLE 1 Baseline patient characteristics
Patient characteristic Bicuspid cohort N = 31 Tricuspid cohort N = 965 P-value
Age, years 76.4 ± 7.9 (31) 80.9 ± 6.4 (965) <0.001
Gender, male 64.5 (20/31) 48.7 (470/965) 0.083
BMI (kg/m2) 28.1 ± 4.91 (30) 26.6 ± 4.82 (956) 0.093
STS score 6.0 ± 10.15 (28) 5.9 ± 6.74 (821) 0.948
EuroSCORE 20II 6.1 ± 7.52 (29) 8.0 ± 8.38 (896) 0.233
Diabetes mellitus, medically treated 16.1 (5/31) 22.5 (217/965) 0.403
History of COPD 9.7 (3/31) 15.7 (151/963) 0.458
NYHA class III or IV 66.7 (20/30) 69.6 (623/895) 0.731
History of hypertension 71.0 (22/31) 79.4 (760/957) 0.254
Coronary artery disease, history 25.8 (8/31) 57.1 (550/964) 0.001
Prior PCI 12.9 (4/31) 30.4 (292/962) 0.037
Prior CABG 3.2 (1/31) 12.6 (122/965) 0.163
Prior implanted pacemaker 12.9 (4/31) 13.4 (129/965) 0.100
Atrial fibrillation, history 25.8 (8/31) 34.2 (326/954) 0.333
Porcelain aorta 6.5 (2/31) 4.3 (41/960) 0.394
Hostile chest/unfavorable chest wall anatomy 0.0 (0/31) 1.0 (10/964) 1.000
Annular calcification (site-reported)
Mild 10.0% (3/30) 19.6% (156/797) 0.192
Moderate 50.0% (15/30) 39.6% (316/797) 0.256
Severe 40.0% (12/30) 40.8% (325/797) 0.932
Cerebrovascular accident, history 16.1 (5/31) 9.3 (89/962) 0.205
Transient ischaemic attack, history 0.0 (0/31) 7.6 (73/958) 0.161
Values are mean ± SD (N) or % (n/N).
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despite repositioning” following implantation of a 25 mm Lotus valve;
the valve was retrieved during the index procedure and a 27 mm Lotus
valve was implanted instead. The bicuspid and tricuspid cohorts had a
similar distribution of valve sizes (27 mm: 39% for bicuspid, 34% for tri-
cuspid; 25 mm: 39% for bicuspid, 40% for tricuspid; 23 mm: 23% for
bicuspid, 26% for tricuspid; P=NS for all) (Figure 2A).
3.3 | Haemodynamic performance
The mean aortic valve gradient was statistically different between
bicuspid and tricuspid patients at baseline (48.7 ± 17.0 mmHg for
bicuspid, 37.6 ± 15.3 mmHg for tricuspid; P < 0.001) but was similar
at discharge (12.4 ± 4.9 mmHg for bicuspid, 10.8 ± 4.5 mmHg for tri-
cuspid; P = 0.059) and 1 year post procedure (13.3 ± 8.2 mmHg for
bicuspid, 10.7 ± 4.9 mmHg for tricuspid; P = 0.167). The mean EOA
measurements were also different at baseline and similar at discharge
and 1 year between the groups; both cohorts demonstrated a signifi-
cant increase in effective orifice area (Baseline EOA: 0.6 ± 0.2 cm2 for
bicuspid, 0.7 ± 0.2 cm2 for tricuspid; P = 0.008. Discharge EOA:
1.6 ± 0.4 cm2 for bicuspid, 1.8 ± 0.5 cm2 for tricuspid; P = 0.052.
1-year EOA: 1.6 ± 0.4 cm2 for bicuspid, 1.8 ± 0.5 cm2 for tricuspid;
P = 0.101) (Figure 3).
Paravalvular leak was not significantly different between the
bicuspid and tricuspid cohorts at either hospital discharge (P = 0.099)
or 1 year post procedure (P = 0.131) (Figure 4).
3.3.1 | Safety
The primary endpoint of all-cause mortality was not significantly differ-
ent between the bicuspid and tricuspid cohorts at 30 days (3.2%
vs. 2.2%, respectively; P = 0.51) or 1 year (9.7% vs. 11.7%, respectively;
FIGURE 2 Lotus valve sizing. A, The distribution of valve sizes used within the bicuspid and tricuspid patient cohorts was similar. B, Undersizing
was more common in patients with bicuspid valves compared to tricuspid valves (29.0% vs. 15.1%; P = 0.04) [Color figure can be viewed at
wileyonlinelibrary.com]
FIGURE 3 Mean aortic valve gradient and effective orifice area. Bicuspid and tricuspid patients both demonstrated a significant change in mean
aortic valve gradient and effective orifice area (EOA) from baseline to discharge, which was maintained at 1 year. Baseline measurements for
mean aortic gradient and mean EOA were different between the bicuspid and tricuspid cohorts at baseline, with no significant difference
observed between groups at discharge or 1 year post-TAVI. Data is core laboratory adjudicated [Color figure can be viewed at
wileyonlinelibrary.com]
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P = 0.74). There were no significant differences between groups for
other principal safety outcomes through 1 year, including cardiovascular
mortality, stroke, hospitalization for valve-related symptoms or worsen-
ing congestive heart failure, and pacemaker implantation (Figure 5).
3.4 | Valve sizing in bicuspid anatomy
Annulus diameter measurements were performed by each site and
valve sizing was determined at the discretion of the operator. Under-
sizing was more common in patients with bicuspid valves compared to
tricuspid valves (9/31 [29.0%] for bicuspid, 112/744 [15.1%] for
tricuspid; P = 0.04) (Figure 2B, Table 2). Of the 31 patients with bicus-
pid anatomy, five had considerable (>10%) undersizing by annulus
area. Echocardiographic data indicates that PVL and haemodynamic
results were good in these patients (Table 3).
4 | DISCUSSION
The principal finding of this study is that outcomes for patients with
bicuspid aortic valves who underwent TAVI with the Lotus Valve in
the “real-world” RESPOND registry were comparable to those with
FIGURE 4 Paravalvular aortic regurgitation. There was no severe PVL observed in either the bicuspid or tricuspid cohort, as adjudicated by the
core laboratory. At hospital discharge, 86.2% of the bicuspid cohort and 92.1% of the tricuspid cohort had no/trace PVL; absence from PVL was
maintained in 85.0% of the bicuspid cohort and 94.9% of the tricuspid cohort at 1 year post-TAVI
FIGURE 5 Principal VARC safety outcomes at 30 days and 1 year post-TAVI. All-cause mortality (RESPOND primary endpoint) was not
significantly different between the bicuspid and tricuspid cohorts at 30 days or 1 year. There were no significant differences between groups for
other principal safety outcomes through 1 year
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tricuspid aortic valves receiving the Lotus Valve. The bicuspid cohort
was significantly younger, which aligns with other descriptions of aor-
tic stenosis in bicuspid valves,1 and the bicuspid cohort presented
with significantly less coronary artery disease. There was no signifi-
cant difference in clinical outcomes between bicuspid and tricuspid
patients, including mortality, stroke, bleeding, vascular complications,
and acute kidney injury. Device success in bicuspid patients was
100%, with no cases of migration, embolization, placement of a sec-
ond valve, or annular rupture. Consistent with the low rates of PVL
with the Lotus Valve in tricuspid anatomy, bicuspid patients in
RESPOND had 0% moderate/severe PVL and only 13.8% mild PVL, as
well as good haemodynamics.
4.1.1 | Challenges of TAVI in bicuspid anatomy
Due to the high level of calcification and eccentric geometry in
patients with bicuspid anatomy, TAVI in bicuspid valves may be sub-
ject to an increased risk of complications related to irregular and
incomplete expansion of the prosthetic valve.9 Asymmetrical expan-
sion of valves has been observed as high as 38% with the S3 valve in
bicuspid anatomy10 and Zegdi et al. describes noncircular stent
deployment as 81% more frequent in bicuspid vs. tricuspid aortic
valves.11 Noncircular or irregular valve expansion may impact valve
hemodynamics and durability. Valve haemodynamics following TAVI,
including mean gradient and effective orifice area, were no different
between bicuspid and tricuspid valves in RESPOND, despite a range
of eccentricity from 1.11 to 1.48 in the bicuspid group (Supporting
Information Table S1). This similarity may be attributed to the inde-
pendent mobility of the Lotus valve leaflets. The Lotus Valve is
designed such that the leaflets are not sutured to the valve frame, and
are therefore not affected by non-circular valve expansion.
Furthermore, heavy calcification and eccentricity of the native
annulus increases the risk of device malapposition and consequently
of PVL. In a comparative analysis from the German TAVI Registry of
bicuspid vs. tricuspid valves, the risk for moderate or greater AR was
higher in patients with bicuspid anatomy receiving CoreValve or
Sapien.12 Mylotte et al. similarly reported a high incidence of post-
implant AR in 139 bicuspid patients undergoing TAVI with Sapien XT
and CoreValve (AR grade ≥ 2 was 28.4%).13 In tricuspid anatomy, the
Lotus Valve has low rates of PVL due to the Adaptive Seal feature.
This seal reduces PVL by conforming to irregular anatomic surfaces,
which may be a crucial attribute for minimizing PVL in bicuspid anat-
omy. In this analysis PVL was similar between tricuspid and bicuspid
patients; there were no cases of moderate or severe PVL in patients
with bicuspid valves, and even mild PVL was seen in only 13.8%. This
result is consistent with the findings of Yoon et al. for PVL with cur-
rent generation TAVI in bicuspid valves.8
Device success is typically lower overall for bicuspid TAVI-patients
as compared to tricuspid TAVI-patients.8 The use of balloon-expanded
valves has been associated with an increased risk of annular rupture
due to overdilation of the prosthesis to treat residual paravalvular
regurgitation.21 The Lotus Valve is fully repositionable and retrievable,
allowing precise positioning in asymmetric anatomy, and avoiding risk
of device migration or embolization. By virtue of its mechanical expan-
sion and the fact that it does not rely on post-dilatation to mitigate
PVL, use of the Lotus Valve may minimize the risk of annular injury
inherent in the procedure. In the entire RESPOND population, there
was only one case of annular rupture (which occurred in a tricuspid
patient following balloon valvuloplasty). Despite frequent aortopathy
(35.4% [11/31] of patients with bicuspid valves in RESPOND had aor-
tic root aneurysms), no cases of dissection were seen. The data from
this subanalysis support these potential advantages of the Lotus Valve
for bicuspid patients as there were no cases of migration, embolization,
deployment of a second valve, or annular rupture in this cohort.
4.1.2 | Valve sizing in bicuspid anatomy
For the RESPOND registry, sizing of the valve was at the discretion of
the implanter. Some clinicians have hypothesized that routine under-
sizing may be beneficial in bicuspid anatomy, allowing fixation and
sealing within the leaflets, with more complete and symmetrical
expansion of the valve frame to optimize haemodynamics and poten-
tially enhance long-term durability. In this analysis five patients
received valves that had >10% undersizing by area; all had good out-
comes with respect to PVL and valve haemodynamics.
Other studies have shown a tendency to oversize TAVI devices in
bicuspid anatomy in an effort to circularize the annulus, prevent mal-
positioning, and reduce PVL, even though oversizing may increase the
TABLE 3 Cases of considerable undersizing (>10%) in bicuspid valves
Patient
Valve size
implanted
Annulus size Mean aortic gradient (mmHg)
PVL at
dischargeArea (mm2)
Area-derived
diameter (mm) Baseline Discharge
1 27 mm 706 30.0 61.6 NR NR
2 27 mm 550 25.7 29.0 12.4 Trace
3 27 mm 784 31.6 53.6 12.9 Mild
4 25 mm 604 28.0 48.2 15.8 None
5 27 mm 691 30.0 22.9 12.0 Trace
Values are means.
NR, not recorded due to death of patient (left ventricular perforation, cardiac tamponade) prior to discharge.
TABLE 2 Valve sizing in RESPOND
Valve sizing range
(per area)
Bicuspid cohort
(N = 31)
Tricuspid cohort
(N = 965) P value
Undersized >10% 16.1% (5/31) 3.6% (27/744) 0.007
Undersized 0 to ≤10% 12.9% (4/31) 11.4% (85/744) 0.773
Oversized 0 to ≤10% 41.9% (13/31) 42.1% (313/744) 0.988
Oversized >10% 29.0% (9/31) 42.9% (319/744) 0.126
Values are % (n/N).
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risk of rupture.8 The combination of controlled mechanical expansion
and the Adaptive Seal of the Lotus Valve may provide a benefit in
addressing these challenges. Specific sizing for bicuspid anatomy with
the Lotus Valve will require further investigation.
In a multivariate analysis of patients treated with the Lotus Valve
in the REPRISE II study,22 the ratio of device area to annulus area was
shown to be a significant independent predictor of PVL (Odds Ratio
[95% CI]: 0.87 [0.83, 0.92]; P < 0.001). Other TAVI studies have like-
wise demonstrated a similar association between valve sizing and
PVL.23–25 However, it is difficult to draw a definitive conclusion
regarding the incidence of PVL as a function of valve oversizing
among bicuspid patients in RESPOND, chiefly due to the small sample
size and low rate of PVL overall in this study. Further examination is
needed to determine whether specific baseline and/or procedural
characteristics influence the development of PVL in bicuspid patients
treated with the Lotus Valve.
4.1.3 | Study limitations
The primary limitation of this study is the small size of the analysis
population. Additionally, RESPOND is a single-arm registry, and not a
randomized study. Preliminary identification of bicuspid anatomy was
site-reported, and although central CT analysis was used to confirm
bicuspid anatomy, it was unfortunately not possible to review baseline
CT scans for all RESPOND patients. In RESPOND, 3% of patients were
identified as having bicuspid aortic valve stenosis; however, other
studies have shown an incidence of approximately 20%.2 It is possible
that initial identification via echocardiography failed to capture all
patients with bicuspid anatomy, underestimating the true number of
bicuspid patients in the population. An additional limitation is that at
the time of this study, the largest available Lotus Valve was 27 mm,
which limits the results to patients with smaller annular diameters.
5 | CONCLUSIONS
TAVI with the Lotus Valve in patients with bicuspid aortic valve anat-
omy treated within the RESPOND registry was associated with good
procedural, clinical, and haemodynamic outcomes.
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